Healthy adults, cefprozil antibiotic trial, Canada
71 stool samples from healthy adult volunteers in Canada, collected before, at the end of and three months after cefprozil antibiotic treatment, to study individual gut microbiome responses and resistance genes. machine-written summary
72 samples · 1,252 runs · CA · Adult · 2015 · 13.55 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 914 sample values (age, antibiotic exposure, bmi, collection date, country, intervention, intervention detail, latitude) |
| ✓ Abstract / description | 1 sample values (health condition detail) |
| ✓ Full text | 2 sample values (health condition, location region) · PMC10036994, PMC10408196, PMC10536327, PMC11121782, PMC12084026, PMC12390848, PMC12764784, PMC13269251, PMC4817689, PMC5154369, PMC6123480, PMC6425642, PMC6451232, PMC6520913, PMC6789009, PMC8288446, PMC9022020, PMC9621045 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| ✓ External resources | 159 sample values (antibiotic exposure, health condition, health condition detail) · from curatedMetagenomicData 3 (cMD 3), GMrepo v3 |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention · arms resolved
24 people have samples in more than one arm.
Antibiotic given as the study intervention (incl. eradication therapy design single_arm_before_after · population healthy_control · Cefprozil (second-generation cephalosporin), 7-day course, healthy volunteers
“administered a second-generation cephalosporin, cefprozil” — abstract:26359913 (study level; per-sample arms are in the intervention column below)
longitudinal
24 of 24 people sampled more than once (72 samples; median 3, up to 3 per person) · follow-up median 3 mo (max 3 mo) · median interval between samples 3 mo (time from collection dates). Schedule stated by the source: “Stool before antibiotic exposure (D0), at end of 7-day treatment (D7), and three months later” (time origin: unknown).
Each row is one person (24 shown); dots are samples at days since that person's first sample.
Genera, mean relative abundance over 71 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 72 | 100% | ||||
| country | 72 | 100% | 72 | |||
| health_condition | 72 | 100% | 71 | 1 | ||
| subject_id | 72 | 100% | 72 | |||
| age_at_collection_days | 72 | 100% | 72 | |||
| bmi | 72 | 100% | 72 | |||
| collection_date | 72 | 100% | 72 | |||
| detailed_location | 72 | 100% | ||||
| health_condition_detail | 72 | 100% | 71 | 1 | ||
| intervention | 72 | 100% | 72 | |||
| location_region | 72 | 100% | 71 | 1 | ||
| sex | 72 | 100% | 72 | |||
| timepoint_label | 72 | 100% | 72 | |||
| antibiotic_exposure | 71 | 99% | 54 | 17 | ||
| intervention_detail | 71 | 99% | 71 | |||
| latitude | 71 | 99% | 71 | |||
| longitude | 71 | 99% | 71 |
- The initial state of the human gut microbiome determines its reshaping by antibiotics. 2016 PMID 26359913 PMC4817689 own_data
- Partial recovery of microbiomes after antibiotic treatment. 2016 PMID 27494088 PMC5154369 own_data
- Mining, analyzing, and integrating viral signals from metagenomic data. 2019 PMID 30890181 PMC6425642 own_data
- Culture-enriched human gut microbiomes reveal core and accessory resistance genes. 2019 PMID 30953542 PMC6451232 own_data
- Antibiotic Treatment Drives the Diversification of the Human Gut Resistome. 2019 PMID 31026582 PMC6520913 own_data
13 more
- Characterization of vancomycin-resistance vanD gene clusters in the human intestinal microbiota by metagenomics and culture-enriched metagenomics. 2023 PMID 36968950 PMC10036994
- GePMI: A statistical model for personal intestinal microbiome identification. 2018 PMID 30210803 PMC6123480
- Individualized recovery of gut microbial strains post antibiotics. 2019 PMID 31632686 PMC6789009
- Dispersal strategies shape persistence and evolution of human gut bacteria. 2021 PMID 34111423 PMC8288446
- Early indicators of microbial strain dysbiosis in the human gastrointestinal microbial community of certain healthy humans and hospitalized COVID-19 patients. 2022 PMID 35449389 PMC9022020
- Functional profile of host microbiome indicates Clostridioides difficile infection. 2022 PMID 36289064 PMC9621045
- Identification of robust and generalizable biomarkers for microbiome-based stratification in lifestyle interventions. 2023 PMID 37553697 PMC10408196
- Uncovering Predictive Factors and Interventions for Restoring Microecological Diversity after Antibiotic Disturbance. 2023 PMID 37764709 PMC10536327
- Bacteroidales-Specific Antimicrobial Genes Can Influence the Selection of the Dominant Fecal Strain of Bacteroides vulgatus and Bacteroides uniformis from the Gastrointestinal Tract Microbial Community. 2024 PMID 38792577 PMC11121782
- Microbes with higher metabolic independence are enriched in human gut microbiomes under stress. 2025 PMID 40377187 PMC12084026
- Microbiota-driven antitumour immunity mediated by dendritic cell migration. 2025 PMID 40659786 PMC12390848
- The gut methanotroph Methylocystis intestini modulates intestinal peristalsis and fat metabolism via reducing methane levels. 2025 PMID 41331251 PMC12764784
- Strain transmission links human microbiomes along the oral-gut axis and across cohabiting individuals. 2026 PMID 42312244 PMC13269251
Archive description
The human gut microbiota is affected by antibiotics, but the heterogeneous response between individuals remains unexplored. To specifically address this question and examine the effect of antibiotics on selection of resistance genes, we administered the second-generation cephalosporin cefprozil to healthy volunteers. Stool samples gathered before antibiotic exposure, at the end of the treatment and three months later were analyzed using shotgun metagenomic sequencing. We show that normal antibiotic treatment can alter the gut microbiome in a specific, reproducible and predictable fashion. Strikingly, we identified a subgroup of participants that were enriched in opportunistic pathogen Enterobacter cloacae after exposure to the antibiotic, an effect linked to lower initial microbiome diversity and to the Bacteroides enterotype. Resistance genes that were not detectable before the treatment were observed after a 7-day course of antibiotic. Knowledge of the initial composition of the microbiome could assist in the prevention of the adverse effects of antibiotics.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of adult by deterministic_prior with confidence 0.90. Assay shotgun_dna.
- host external_curation.infant_catalog · “infant triage reason_code age_adult_only”
- body site study.title · “of the human gut microbiome determines its”
- body site study.description · “The human gut microbiota is affected”
- life stage external_curation.infant_catalog · “infant triage reason_code age_adult_only”
- life stage study.description · “cefprozil to healthy volunteers . Stool samples”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMEA3182045 | age_at_collection_days | 10601.0 | R1 | 0.85 | sample.attr.host_age | 29 |
| SAMEA3182045 | antibiotic_exposure | no | R1 | 0.70 | sample.name_rule:alias | P1E0 |
| SAMEA3182093 | antibiotic_exposure | yes | R2 | 0.75 | external.cmd source | antibiotics_current_use: Yes |
| SAMEA3182045 | bmi | 22.16 | R1 | 0.85 | biosample.attribute:host height+host total mass | height 1.9 m; mass 80 kg |
| SAMEA3182097 | bmi | 24.72 | R1 | 0.80 | biosample.attribute:host total mass;host height | host total mass: 79.2; host height: 1.79 |
| SAMEA3182045 | collection_date | 2011-11-01 | R1 | 0.90 | biosample.attribute:collection_date | 2011-11-01 |
| SAMEA3182097 | collection_date | 2012-05-15 | R1 | 0.85 | biosample.attribute:collection date | collection date: 2012-05-15 |
| SAMEA3182045 | country | CA | R1 | 0.90 | sample.attr.geographic_location_country_and_or_sea | Canada |
| SAMEA3182045 | health_condition | healthy_control | R2 | 0.75 | external.cmd source | disease: Healthy |
| SAMEA3182069 | health_condition | healthy_control | R2 | 0.75 | external.gmrepo source | phenotype: Health |
| SAMEA3182097 | health_condition | healthy_control | R3 | 0.70 | paper.fulltext.methods | 24 healthy participants enrolled in this study |
| SAMEA3182045 | health_condition_detail | Healthy | R2 | 0.75 | external.cmd source | disease: Healthy |
| SAMEA3182069 | health_condition_detail | Health | R2 | 0.75 | external.gmrepo source | phenotype: Health |
| SAMEA3182097 | health_condition_detail | Healthy volunteers with no stated disease condition | R4 | 0.50 | study.description | healthy volunteers |
| SAMEA3182045 | intervention | no_intervention | R1 | 0.80 | biosample.attribute:Timepoint | Timepoint: 0 |
| SAMEA3182097 | intervention | antibiotic | R1 | 0.85 | biosample.attribute:Type | Type: Exposed |
| SAMEA3182045 | intervention_detail | Timepoint = 0 (before intervention start) | R1 | 0.80 | biosample.attribute:Timepoint | Timepoint: 0 |
| SAMEA3182045 | latitude | 46.8033 | R1 | 0.90 | biosample.attribute:geographic_location_latitude+geographic_location_longitude | 46.8032826 -71.242796 |
| SAMEA3182045 | location_region | Quebec | R1 | 0.60 | biosample.attribute:geographic_location_latitude+geographic_location_longitude | 46.8032826 -71.242796 |
| SAMEA3182097 | location_region | Quebec City region | R3 | 0.70 | paper.fulltext.methods | young adults from the Quebec City region (Canada) |
| SAMEA3182045 | longitude | -71.2428 | R1 | 0.90 | biosample.attribute:geographic_location_latitude+geographic_location_longitude | 46.8032826 -71.242796 |
| SAMEA3182045 | sex | male | R1 | 0.90 | sample.attr.host_sex | male |
| SAMEA3182045 | subject_id | 1 | R1 | 0.85 | sample.attr.host_subject_id | 1 |
| SAMEA3182097 | subject_id | 5 | R1 | 0.85 | biosample.attribute:host subject id | host subject id: 5 |
| SAMEA3182045 | timepoint_label | 0 | R1 | 0.85 | sample.attr.timepoint | 0 |
| SAMEA3182097 | timepoint_label | 90 | R1 | 0.85 | biosample.attribute:Timepoint | Timepoint: 90 |
Sequencing
1,252 runs over 72 samples · mean 0.78 Gbp per run (median 0.81 Gbp, total 982.56 Gbp; 1,252 runs with a base count) · layout PAIRED 1,252 · platform ILLUMINA 1,252 · models Illumina HiSeq 1000 (1,252) · 90% of runs with a Sandpiper profile · first public 2015-03-05
Authors (84)
Raymond F first · Ouameur AA · Déraspe M · Iqbal N · Gingras H · Dridi B · Leprohon P · Plante PL · Giroux R · Bérubé · Bérubé È · Frenette J · Boudreau DK · Simard JL · Chabot I · Domingo MC · Trottier S · Boissinot M · Huletsky A · Roy PH · Ouellette M · Bergeron MG · Corbeil J last · Koo H first · Morrow CD last · Orihara K first · Yahagi K · Saito Y · Watanabe Y · Sasai T · Hara T · Tsukuda N · Oki K · Fujimoto J · Matsuki T last · Chen J first · Zhu J · Lu W · Wang H · Pan M · Tian P · Zhao J · Zhang H · Chen W last · Mancabelli L first · Milani C · De Biase R · Bocchio F · Fontana F · Lugli GA · Alessandri G · Tarracchini C · Viappiani A · De Conto F · Nouvenne A · Ticinesi A · Bussolati O · Meschi T · Cecchi R · Turroni F · Ventura M last · van Sinderen D · Schroer HW first · Beghini F · Raygoza Garay JA · Christakis NA · Bosch DE last · Heidrich V first · Fackelmann G · Ricci L · Spadazzi R · Baldanzi G · Punčochář M · Catassi G · Marchi P · Modesto M · Piccinno G · Porcari S · Rondinella D · Asnicar F · Valles-Colomer M · Mattarelli P · Ianiro G · Segata N last
Downloads
PRJEB8094.csv.gz (3.8 KB) · parquet (75.9 KB) — all 72 samples, every field with route and confidence · PRJEB8094_determinations.csv.gz (11.3 KB) — 1,076 evidence rows